Palatin Technologies, Inc. PTN

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.

Moby summary of Palatin Technologies, Inc.'s Q3 2026 earnings call

Palatin Technologies Inc (PTN) reports significant revenue growth and strategic partnerships, while navigating increased expenses and development delays.

Palatin Techs (AMEX:PTN) held its third-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. Access the full call at https://www.webcaster5.com/Webcast/Page/2953/54002 Summary Palatin Techs reported $3.9 million in collaboration and license revenue for Q3 2026, marking an increase from no revenue in the prior year, p

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system, today announced financial results for its fiscal third quarter ended March 31, 2026, and provided a business update.

Moby summary of Palatin Technologies, Inc.'s Q2 2026 earnings call

Despite a significant net loss, Palatin Technologies Inc (PTN) strengthens its financial position with a successful public offering and advances in its obesity treatment pipeline.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results for its fiscal second quarter ended December 31, 2025, and provided a corporate update.

Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced underwritten public offering of 2,795,384 shares of its common stock (or pre-funded warrants in lieu thereof), which included the full exercise of the underwriters' option to purchase 364,615 additional shares of common